|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study显示文摘 | Pierre Fenaux Ghulam J Mufti Eva Hellstrom-Lindberg Valeria Santini Carlo Finelli Aristoteles Giagounidis Robert Schoch Norbert Gattermann Guillermo Sanz Alan List Steven D Gore John F Seymour John M Bennett John Byrd Jay Backstrom Linda Zimmerman David M | 2009 | Lancet Oncology2009，，： | 2 |
| 2 | IneffectⅣe hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome显示文摘 | GATTERMANN N WULFERT M JUNGE B | 2004 | Blood2004，103，： | 1 |
| 3 | Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C显示文摘 | Fenaux P Gattermann N Seymour JF | 2010 | Br J Hematol2010，149，2： | 1 |
| 4 | Effects of social stress on behavior and corpus luteum in female golden hamsters(Mesocricetus auratus)显示文摘 | FRITZSCHE P RIEK M GATTERMANN R | 2000 | Physiology&Behavior2000，68，5： | 1 |
| 5 | :Nilotinib(formerlyAMN107),a highly selective BCR-ABL tyrosine kinase inhibitor,is effective in patients with Philadelphia chromosome-positive chron-ic myelogenous leukemia in chronic phase following imatinib resist-ance and intolerance显示文摘 | Kantarjian HM Giles F Gattermann N | 2007 | Blood2007，110，35： | 1 |
| 6 | Nilotinib (formerly AMN107), a high selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromo-some-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance显示文摘 | KANTARJIAN HM GILES F GATTERMANN N | 2007 | Blood2007，110，10： | 1 |
| 7 | Iron overload in MDS-pathophysiology,diagnosis,and complications显示文摘 | Gattermann N Rachmilewitz EA | | 0，，1： | 1 |
| 8 | Phase 2 study of oral panobinostat (LBH589) with or without eryth- ropoietin in heavily transfusion-dependent IPSS low or int- 1 MDS patients显示文摘 | Platzbecker U A1-Ali H K Gattermann N | 2014 | Leukemia2014，28，3： | 1 |
| 9 | Iron overload in MDS-pathophysiology,diagnosis and complications显示文摘 | Gattermann N Rachmilewitz EA | | 0，，： | 1 |
| 10 | First seven microsatellites developed for the Peking duck (Anas platyrhynchos) 显示文摘 | Maak S Neumann K Gattermann R | 2000 | Animal Genetics2000，31，： | 1 |
| 11 | Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload显示文摘 | Gattermann N | 2007 | Leuk Res2007，31，3： | 1 |
| 12 | Diagnosis and the rapystrategy in myelodysplastic syndromes 显示文摘 | Gattermann N Aul C | 1996 | Schweiz Rundsch Med Prax1996，85，： | 1 |
| 13 | First seven microsatellites developed for the Peking duck (Anas platyrhynchos)显示文摘 | Maak S Neumann K Gattermann R | 2000 | Anim Genet2000，31，： | 1 |
| 14 | Hemato- logic responses in myelodysplastie syndromes (MDS) patients treated with deferasirox: an EPIC post-boc analysis using interna- tlonal working group ( IWG ) 2006 criteria 显示文摘 | GATTERMANN N FINELLI C MATTEO DP | 2010 | Blood2010，116，： | 1 |
| 15 | Iron overload in MDS- pathophysiology, diagnosis, and complications显示文摘 | Gattermann N Rachmilewitz EA | 2011 | Ann Hematol2011，90，1： | 1 |
| 16 | Risk assessment in chronic myelomonocytic leuke-mia显示文摘 | GERMING U KUNDGEN A GATTERMANN N | 2004 | Leuk Lymphoma2004，45，： | 1 |
| 17 | Rrfractory anemia with of excess blasts in transformation: analysis if reclassification according to the WHO proposals显示文摘 | Stupp C Gattermann N Giagounidis A | 2003 | Leuk Res2003，27，5： | 1 |
| 18 | Ueber die verseifung von phenol~thern und derivaten derselben, sowie von sure thern dutch aluminiumchlorid显示文摘 | Hartmann C Gattermann L | | Eur J Inorg Chem0，25，2： | 1 |
| 19 | Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload显示文摘 | Gattermann N | 2008 | Int J Hematol2008，88，1： | 1 |
| 20 | Two types of acquired idiopathic sideroblastic anaemia (AISA)显示文摘 | Gattermann N Aul C Schneider W | 1990 | Br J Haematol1990，74，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员